We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Barzolvolimab is an anti-KIT monoclonal antibody. 75% of ...
BOSTON -- Treatment with an investigational anti-KIT monoclonal antibody induced clinically meaningful responses in the two most common forms of chronic inducible urticaria, a dose-ranging phase II ...
Data on new treatments for chronic spontaneous urticaria (CSU) show significant symptom reduction very early during treatment. There are multiple new drugs and mechanisms that are very promising to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback